BIVINasdaq

BIOVIE INC.

Healthcare·Infectious Disease·Phase 3·Carson City, NV, United States
Infectious Disease

BIOVIE INC. (BIVI): 2 pipeline candidates · 1 upcoming catalyst · ~6 mo cash runway · 2 clinical trials. Updated within the last hour.

5.5/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway1.6

5.7 months

Financial Health9.8

D/E 0.12 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth4.6

2 candidates

Catalyst Momentum3.0

1 upcoming, next in ~104d

Insider SignalN/A

N/A

A transparent, data-derived signal for BIOVIE INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$12.4M

Cash

$13.1M

Quarterly Burn

$7.4M

Runway

5.7 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Dec 2026
Today~7 mo out
Catalyst within runway

Pipeline (2 candidates)

DrugPhase
bezisterim (NE3107)Phase 3
NE3107Phase 2

Upcoming Catalysts (1)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

33

Total value held

$1.4M

HolderSharesValue
diametric capital, lp370,000$518K
vanguard capital management llc168,134$235K
prelude capital management, llc92,063$129K
geode capital management, llc84,203$118K
morgan stanley75,221$105K
renaissance technologies llc67,918$95K
citadel advisors llc45,292$63K
vanguard fiduciary trust co37,557$53K
jane street group, llc22,791$32K
xtx topco ltd21,226$30K

Showing top 10 of 33 institutional holders of BIOVIE INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

2 clinical trials·CEO: Mr. Cuong Viet Do M.B.A.

Frequently asked questions

How many drug candidates are in BIOVIE INC.'s pipeline?

BIOVIE INC. (BIVI) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is BIOVIE INC.'s lead drug candidate?

BIOVIE INC.'s most advanced tracked candidate is bezisterim (NE3107) (Phase 3) for Long COVID.

What is BIOVIE INC.'s next catalyst?

BIOVIE INC.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: bezisterim" — expected September 30, 2026.

What is BIOVIE INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, BIOVIE INC. has approximately 5.7 months of cash runway.

What is BIOVIE INC.'s market capitalization?

BIOVIE INC.'s market capitalization is approximately $12.4M.

Get the full picture on BIOVIE INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.